Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
NEW YORK, Sept. 19, 2016 -- Provista Diagnostics, Inc., today announces that David Reese, Ph.D., President and Chief Executive Officer, will deliver a poster presentation at the 15th Human Proteome Organization World Congress, taking place September 18-22, 2016 at the Taipei International Convention Center in Taipei, Taiwan.
“We are excited for the opportunity to present on Provista’s serum-based combinatorial proteomic biomarker assay, called Videssa® Breast,” said Dr. Reese. “Particularly because the test results are unaffected by dense breast tissue, this assay is an important advancement in proteomic technologies for addressing the many challenges clinicians face in detecting breast cancer in their patients.”
Frequently, proteomic measurements are affected by several biological processes such as tumor development and progression. For this reason, it is very exciting that the performance of Videssa Breast was not affected by increased breast density in women. In previous study results, Provista showed this effect in women ages 25 to 50; however, this current study confirms those results in women who are mostly post-menopausal (ages 50 – 75). In both groups of women, detecting cancer is difficult because breast density “masks” the cancer from detection. In such cases, women with extremely dense breasts face a worse prognosis when breast imaging does eventually find the tumor.
Dr. Reese will be presenting on Tuesday, September 20, 2016 at 9:30 a.m. in Banquet Hall, 3F; session 68.
Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov
About Provista
Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).
About the Human Proteome Organization World Congress
The Human Proteome Organization (HUPO) is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
Learn more about HUPO on their official website.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Jessica C. Schultz JPA Health Communications 202-591-4005 [email protected]
